tiprankstipranks
Precision BioSciences reports Q4 EPS ($2.22), consensus ($2.94)
PremiumThe FlyPrecision BioSciences reports Q4 EPS ($2.22), consensus ($2.94)
6d ago
Precision BioSciences: Promising Gene Editing Advancements and Strategic Positioning in DMD and HBV Markets
Premium
Ratings
Precision BioSciences: Promising Gene Editing Advancements and Strategic Positioning in DMD and HBV Markets
12d ago
Buy Rating for Precision BioSciences Driven by Promising Preclinical Data and Potential of ARCUS Nucleases in DMD Treatment
Premium
Ratings
Buy Rating for Precision BioSciences Driven by Promising Preclinical Data and Potential of ARCUS Nucleases in DMD Treatment
13d ago
Buy Rating for Precision BioSciences: Promising Clinical Data and Undervaluation Highlight Favorable Risk/Reward Scenario
PremiumRatingsBuy Rating for Precision BioSciences: Promising Clinical Data and Undervaluation Highlight Favorable Risk/Reward Scenario
1M ago
Encouraging Initial Data for Precision BioSciences’ PBGENE-HBV Supports Positive Analyst Rating and $60 Target Price
Premium
Ratings
Encouraging Initial Data for Precision BioSciences’ PBGENE-HBV Supports Positive Analyst Rating and $60 Target Price
1M ago
Positive Outlook for Precision BioSciences: Promising Gene-Editing Therapy for Hepatitis B and Strong Financial Position
Premium
Ratings
Positive Outlook for Precision BioSciences: Promising Gene-Editing Therapy for Hepatitis B and Strong Financial Position
1M ago
Precision BioSciences upgraded to Outperform from Market Perform at BMO Capital
PremiumThe FlyPrecision BioSciences upgraded to Outperform from Market Perform at BMO Capital
3M ago
Precision BioSciences to present preclinical PBGENE-HBV data
Premium
The Fly
Precision BioSciences to present preclinical PBGENE-HBV data
5M ago
Precision BioSciences reports Q3 EPS ($2.25), consensus ($1.92)
Premium
The Fly
Precision BioSciences reports Q3 EPS ($2.25), consensus ($1.92)
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100